8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

October 13, 2009

(Exact name of registrant as specified in its charter)

New Jersey	I-3215	22-1024240
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933

(Address of Principal Executive Offices)

 (Zip Code)

Registrant’s telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

               CFR 240.14d-2(b))

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

               CFR 240.13e-4(c))

Item 2.02                      Results of Operations and Financial Condition

On October 13, 2009, Johnson & Johnson issued the attached press release announcing its sales and earnings for the third quarter ended September 27, 2009.

Item 9.01            Financial Statements and Exhibits

Exhibit No.	Description of Exhibit
99.15	Press Release dated October 13, 2009 for the period ended September 27, 2009.
99.2O	Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the third quarter.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Johnson & Johnson
		(Registrant)
Date: October 13, 2009	By:	/s/ Stephen J. Cosgrove
		Stephen J. Cosgrove Controller (Principal Accounting Officer)

EX-99.15 OTH FIN ST

Exhibit 99.15

Johnson & Johnson Reports 2009 Third-Quarter Results:

Sales of $15.1 Billion Decreased 5.3% Versus 2008 Third Quarter

 EPS of $1.20 increased 2.6% Versus 2008 Third Quarter

New Brunswick, NJ (October 13, 2009) – Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%.  Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

Net earnings and diluted earnings per share for the third quarter of 2009 were $3.3 billion and $1.20, respectively, representing increases of 1.1% and 2.6%, as compared to the same period in 2008.  The Company raised its earnings guidance for full-year 2009 to $4.54 - $4.59 per share, which excludes the impact of  special items.

“We continue to successfully manage our broad base of businesses and deliver solid earnings despite the impact of patent expirations and the challenges posed by the current economic environment,” said William C. Weldon, Chairman and Chief Executive Officer. “We completed multiple acquisitions and strategic collaborations and received several new product approvals in the quarter that will benefit patients worldwide and drive future growth.”

Worldwide Consumer sales of $4.0 billion for the third quarter represented a decrease of 2.7% versus the prior year with an increase of 1.1% operationally and a negative impact from currency of 3.8%. Domestic sales decreased 4.4%; international sales decreased 1.4%, which reflected an operational increase of 5.2% and a negative currency impact of 6.6%.

Contributing to operational sales growth during the quarter were sales of Dabao skin care products; AVEENO® skin care products; SPLENDA® No Calorie Sweetener; Le Petit Marseillais® beauty care products; and LISTERINE® antiseptic mouthrinse.  Other growth drivers were sales from the acquisition of Vania Expansion SNC.

Worldwide Pharmaceutical sales of $5.3 billion for the third quarter represented a decrease of 14.1%  versus the prior year with an operational decline of 11.9% and a negative impact from currency of 2.2%. Domestic sales decreased 19.2%; international sales decreased 7.1%, which reflected an operational decrease of 1.9% and a negative currency impact of 5.2%.

REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases, demonstrated solid sales performance during the quarter. Several other pharmaceutical products had strong growth including  PREZISTA® (darunavir), a treatment for HIV;  VELCADE® (bortezomib), a treatment for multiple myeloma; and RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment, an antipsychotic medication. Sales results of TOPAMAX® (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by generic competition.

During the quarter, the U.S. Food and Drug Administration (FDA) approved STELARATM (ustekinumab) for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.  The FDA also approved INVEGA® SUSTENNA™ (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults; the first once-monthly, long-acting, injectable atypical antipsychotic approved in the U.S. for this use. In addition, the FDA approved the Supplemental New Drug Application for INVEGA® (paliperidone) extended-release tablets for the acute treatment of schizoaffective disorder either as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants.

On Oct. 6, the European Commission approved SIMPONI™ (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis, active and progressive psoriatic arthritis and severe, active ankylosing spondylitis.

During the quarter, the Company completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program as well as an equity investment in Elan. Additionally, the Company announced that it had entered into a licensing and collaboration agreement with Gilead Sciences, Inc., for the development and commercialization of a new fixed dose combination of investigational compound TMC278 (rilpivirine hydrochloride 25 mg) and Gilead’s TRUVADA® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for treatment-naïve adult patients with HIV-1.

Early in the fourth quarter, the Company announced that it had entered into a strategic collaboration with Crucell, N.V., focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases. The agreement also included an 18% equity investment in Crucell, N.V.

Worldwide Medical Devices and Diagnostics sales of $5.8 billion for the third quarter represented an increase of 2.3% versus the prior year with an operational increase of 4.1% and a negative currency impact of 1.8%. Domestic sales increased 4.5%; international sales increased 0.5%, which reflected an operational increase of 3.8% and a negative currency impact of 3.3%.

Primary contributors to the operational growth included Ethicon’s surgical care  and aesthetics products; Ethicon Endo-Surgery’s minimally invasive products; DePuy’s orthopaedic joint reconstruction, spine, and sports medicine businesses; and Ortho-Clinical Diagnostics’ professional products. This growth was partially offset by lower sales in the Cordis franchise, reflecting strong competition in the drug-eluting stent market, and the 2008 divestiture of the Professional Wound Care products in our Ethicon business.

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 117,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after

the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company’s website at www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.comor on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

EX-99.2O OTH FIN ST

Exhibit 99.2O

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)	THIRD QUARTER
	2009			2008			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$      15,081		100.0	$      15,921		100.0	(5.3)
Cost of products sold	4,434		29.4	4,774		30.0	(7.1)
Selling, marketing and administrative expenses	4,767		31.6	5,195		32.6	(8.2)
Research expense	1,617		10.7	1,861		11.7	(13.1)
Interest (income)expense, net	114		0.7	25		0.2
Other (income)expense, net	(96)		(0.6)	(224)		(1.4)
Earnings before provision for taxes on income	4,245		28.2	4,290		26.9	(1.0)
Provision for taxes on income	900		6.0	980		6.1	(8.2)
Net earnings	$        3,345		22.2	$       3,310		20.8	1.1
Net earnings per share  (Diluted)	$         1.20			$         1.17			2.6
Average shares outstanding  (Diluted)	2,793.0			2,831.3
Effective tax rate	21.2	%		22.8	%

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)	NINE MONTHS
	2009			2008			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$       45,346		100.0	$       48,565		100.0	(6.6)
Cost of products sold	13,135		29.0	14,139		29.1	(7.1)
Selling, marketing and administrative expenses	14,172		31.3	15,825		32.6	(10.4)
Research expense	4,773		10.5	5,469		11.3	(12.7)
In-process research & development	-		-	40		0.1
Interest (income)expense, net	280		0.6	57		0.1
Other (income)expense, net	(165)		(0.4)	(377)		(0.8)
Earnings before provision for taxes on income	13,151		29.0	13,412		27.6	(1.9)
Provision for taxes on income	3,091		6.8	3,177		6.5	(2.7)
Net earnings	$       10,060		22.2	$       10,235		21.1	(1.7)
Net earnings per share  (Diluted)	$           3.61			$           3.60			0.3
Average shares outstanding  (Diluted)	2,787.9			2,847.8
Effective tax rate	23.5	%		23.7	%
Adjusted earnings before provision for taxes and net earnings (A)
Earnings before provision for taxes
on income	$      13,151		29.0	$       13,452	(1)	27.7	(2.2)
Net earnings	$       10,060		22.2	$       10,275	(1)	21.2	(2.1)
Net earnings per share  (Diluted)	$           3.61			$           3.61	(1)		0.0
Effective tax rate	23.5	%		23.6	%
(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income and net earnings and net earnings per share (diluted) is IPR&D of $40 million with no tax benefit and $0.01 per share, respectively.

(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, they may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as business development activities (including IPR&D at acquisition or upon attainment of milestones and any extraordinary expenses), strategic developments (including restructuring and product line changes), significant litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets.  Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, merger-related or other restructuring charges, or amortization of purchased intangibles, and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)	THIRD QUARTER
					Percent Change
	2009		2008		Total			Operations			Currency
Sales to customers by
segment of business
Consumer
U.S.	$	1,691		1,769		(4.4	) %		(4.4	)		-
International		2,298		2,330		(1.4	)		5.2			(6.6	)
		3,989		4,099		(2.7	)		1.1			(3.8	)
Pharmaceutical
U.S.		2,857		3,538		(19.2	)		(19.2	)		-
International		2,392		2,575		(7.1	)		(1.9	)		(5.2	)
		5,249		6,113		(14.1	)		(11.9	)		(2.2	)
Med Devices & Diagnostics
U.S.		2,766		2,648		4.5			4.5			-
International		3,077		3,061		0.5			3.8			(3.3	)
		5,843		5,709		2.3			4.1			(1.8	)
U.S.		7,314		7,955		(8.1	)		(8.1	)		-
International		7,767		7,966		(2.5	)		2.4			(4.9	)
Worldwide	$	15,081		15,921		(5.3	) %		(2.8	)		(2.5	)

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)	NINE MONTHS
						Percent Change
		2009		2008		Total			Operations			Currency
Sales to customers by
segment of business
Consumer
U.S.		$	5,125		5,282		(3.0	) %		(3.0	)		-
International			6,429		6,917		(7.1	)		4.1			(11.2	)
			11,554		12,199		(5.3	)		1.0			(6.3	)
Pharmaceutical
U.S.			9,703		11,401		(14.9	)		(14.9	)		-
International			6,824		7,481		(8.8	)		1.4			(10.2	)
			16,527		18,882		(12.5	)		(8.5	)		(4.0	)
Med Devices & Diagnostics
U.S.			8,194		7,959		3.0			3.0			-
International			9,071		9,525		(4.8	)		3.7			(8.5	)
			17,265		17,484		(1.3	)		3.3			(4.6	)
U.S.			23,022		24,642		(6.6	)		(6.6	)		-
International			22,324		23,923		(6.7	)		3.1			(9.8	)
Worldwide		$	45,346		48,565		(6.6	) %		(1.8	)		(4.8	)

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)	THIRD QUARTER
					Percent Change
	2009		2008		Total			Operations			Currency
Sales to customers by
geographic area
U.S.	$	7,314		7,955		(8.1	) %		(8.1	)		-
Europe		3,879		4,076		(4.8	)		2.1			(6.9	)
Western Hemisphere excluding U.S.		1,338		1,461		(8.4	)		1.5			(9.9	)
Asia-Pacific, Africa		2,550		2,429		5.0			3.5			1.5
International		7,767		7,966		(2.5	)		2.4			(4.9	)
Worldwide	$	15,081		15,921		(5.3	) %		(2.8	)		(2.5	)

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)	NINE MONTHS
						Percent Change
		2009		2008		Total			Operations			Currency
Sales to customers by
geographic area
U.S.		$	23,022		24,642		(6.6	) %		(6.6	)		-
Europe			11,522		12,931		(10.9	)		1.2			(12.1	)
Western Hemisphere excluding U.S.			3,615		3,986		(9.3	)		5.8			(15.1	)
Asia-Pacific, Africa			7,187		7,006		2.6			5.1			(2.5	)
International			22,324		23,923		(6.7	)		3.1			(9.8	)
Worldwide		$	45,346		48,565		(6.6	) %		(1.8	)		(4.8	)

	REPORTED SALES vs. PRIOR PERIOD
	$MM
	THIRD QUARTER
			% Change
	2009	2008	Reported	Operational (1)	Currency
CONSUMER SEGMENT (2)
SKIN CARE
US	370	358	3.4%	3.4%	-
Intl	472	500	(5.6%)	(0.1%)	(5.5%)
WW	842	858	(1.9%)	1.3%	(3.2%)
BABY CARE
US	102	114	(10.5%)	(10.5%)	-
Intl	442	472	(6.4%)	(0.7%)	(5.7%)
WW	544	586	(7.2%)	(2.6%)	(4.6%)
ORAL CARE
US	187	204	(8.3%)	(8.3%)	-
Intl	223	230	(3.0%)	4.8%	(7.8%)
WW	410	434	(5.5%)	(1.4%)	(4.1%)
OTC/NUTRITIONALS
US	732	778	(5.9%)	(5.9%)	-
Intl	666	661	0.8%	8.0%	(7.2%)
WW	1,398	1,439	(2.8%)	0.5%	(3.3%)
WOMEN'S HEALTH
US	142	164	(13.4%)	(13.4%)	-
Intl	360	346	4.0%	11.7%	(7.7%)
WW	502	510	(1.6%)	3.6%	(5.2%)
WOUND CARE / OTHER
US	158	151	4.6%	4.6%	-
Intl	135	121	11.6%	18.0%	(6.4%)
WW	293	272	7.7%	10.5%	(2.8%)
TOTAL CONSUMER
US	1,691	1,769	(4.4%)	(4.4%)	-
Intl	2,298	2,330	(1.4%)	5.2%	(6.6%)
WW	3,989	4,099	(2.7%)	1.1%	(3.8%)
Note: See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD
	$MM
	NINE MONTHS
			% Change
	2009	2008	Reported	Operational (1)	Currency
CONSUMER SEGMENT (2)

SKIN CARE
US	1,204	1,119	7.6%	7.6%	-
Intl	1,313	1,418	(7.4%)	3.0%	(10.4%)
WW	2,517	2,537	(0.8%)	5.0%	(5.8%)
BABY CARE
US	308	340	(9.4%)	(9.4%)	-
Intl	1,233	1,351	(8.7%)	0.7%	(9.4%)
WW	1,541	1,691	(8.9%)	(1.4%)	(7.5%)
ORAL CARE
US	549	588	(6.6%)	(6.6%)	-
Intl	612	640	(4.4%)	8.3%	(12.7%)
WW	1,161	1,228	(5.5%)	1.1%	(6.6%)
OTC/NUTRITIONALS
US	2,137	2,299	(7.0%)	(7.0%)	-
Intl	1,919	2,139	(10.3%)	1.8%	(12.1%)
WW	4,056	4,438	(8.6%)	(2.8%)	(5.8%)
WOMEN'S HEALTH
US	443	470	(5.7%)	(5.7%)	-
Intl	963	1,005	(4.2%)	7.2%	(11.4%)
WW	1,406	1,475	(4.7%)	3.1%	(7.8%)
WOUND CARE / OTHER
US	484	466	3.9%	3.9%	-
Intl	389	364	6.9%	18.8%	(11.9%)
WW	873	830	5.2%	10.5%	(5.3%)
TOTAL CONSUMER
US	5,125	5,282	(3.0%)	(3.0%)	-
Intl	6,429	6,917	(7.1%)	4.1%	(11.2%)
WW	11,554	12,199	(5.3%)	1.0%	(6.3%)
Note: See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD
	$MM
	THIRD QUARTER
			% Change
	2009	2008	Reported	Operational (1)	Currency
PHARMACEUTICAL SEGMENT (2)

ACIPHEX/PARIET
US	131	130	0.8%	0.8%	-
Intl	130	152	(14.5%)	(9.0%)	(5.5%)
WW	261	282	(7.4%)	(4.4%)	(3.0%)
CONCERTA
US	205	190	7.9%	7.9%	-
Intl	79	208	(62.0%)	(59.2%)	(2.8%)
WW	284	398	(28.6%)	(27.2%)	(1.4%)
DURAGESIC/FENTANYL TRANSDERMAL
US	38	54	(29.6%)	(29.6%)	-
Intl	168	205	(18.0%)	(15.2%)	(2.8%)
WW	206	259	(20.5%)	(18.3%)	(2.2%)
LEVAQUIN/FLOXIN
US	294	313	(6.1%)	(6.1%)	-
Intl	17	20	(15.0%)	0.3%	(15.3%)
WW	311	333	(6.6%)	(5.7%)	(0.9%)
PROCRIT/EXPREX
US	299	334	(10.5%)	(10.5%)	-
Intl	243	285	(14.7%)	(9.6%)	(5.1%)
WW	542	619	(12.4%)	(10.0%)	(2.4%)
RAZADYNE/REMINYL
US	1	31	(96.8%)	(96.8%)	-
Intl	96	107	(10.3%)	(3.8%)	(6.5%)
WW	97	138	(29.7%)	(24.7%)	(5.0%)
REMICADE
US	822	778	5.7%	5.7%	-
US Exports (4)	208	198	5.1%	5.1%	-
Intl	6	2	200.0%	198.7%	1.3%
WW	1,036	978	5.9%	5.9%	-

Note: See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD
	$MM
	THIRD QUARTER
			% Change
	2009	2008	Reported	Operational (1)	Currency
PHARMACEUTICAL SEGMENT (2) (CONTINUED)

RISPERDAL/RISPERIDONE
US	35	122	(71.3%)	(71.3%)	-
Intl	157	198	(20.7%)	(21.4%)	0.7%
WW	192	320	(40.0%)	(40.4%)	0.4%
RISPERDAL CONSTA
US	129	118	9.3%	9.3%	-
Intl	224	220	1.8%	10.2%	(8.4%)
WW	353	338	4.4%	9.9%	(5.5%)
TOPAMAX
US	72	606	(88.1%)	(88.1%)	-
Intl	103	122	(15.6%)	(7.9%)	(7.7%)
WW	175	728	(76.0%)	(74.7%)	(1.3%)
VELCADE
US	-	1	(100.0%)	(100.0%)	-
Intl	231	189	22.2%	31.1%	(8.9%)
WW	231	190	21.6%	30.5%	(8.9%)
OTHER
US	623	663	(6.0%)	(6.0%)	-
Intl	938	867	8.2%	13.6%	(5.4%)
WW	1,561	1,530	2.0%	5.1%	(3.1%)
TOTAL PHARMACEUTICAL
US	2,857	3,538	(19.2%)	(19.2%)	-
Intl	2,392	2,575	(7.1%)	(1.9%)	(5.2%)
WW	5,249	6,113	(14.1%)	(11.9%)	(2.2%)
MAJOR NEW PHARMACEUTICAL PRODUCTS (5)
PREZISTA
US	78	34	129.4%	129.4%	-
Intl	73	45	62.2%	77.0%	(14.8%)
WW	151	79	91.1%	99.5%	(8.4%)
INVEGA
US	61	73	(16.4%)	(16.4%)	-
Intl	36	16	125.0%	142.5%	(17.5%)
WW	97	89	9.0%	12.3%	(3.3%)
Note: See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD
	$MM
	NINE MONTHS
			% Change
	2009	2008	Reported	Operational (1)	Currency
PHARMACEUTICAL SEGMENT (2)

ACIPHEX/PARIET
US	397	399	(0.5%)	(0.5%)	-
Intl	387	485	(20.2%)	(9.3%)	(10.9%)
WW	784	884	(11.3%)	(5.3%)	(6.0%)
CONCERTA
US	707	622	13.7%	13.7%	-
Intl	238	345	(31.0%)	(20.8%)	(10.2%)
WW	945	967	(2.3%)	1.3%	(3.6%)
DURAGESIC/FENTANYL TRANSDERMAL
US	163	199	(18.1%)	(18.1%)	-
Intl	492	565	(12.9%)	(4.3%)	(8.6%)
WW	655	764	(14.3%)	(8.0%)	(6.3%)
LEVAQUIN/FLOXIN
US	1,045	1,117	(6.4%)	(6.4%)	-
Intl	53	63	(15.9%)	1.4%	(17.3%)
WW	1,098	1,180	(6.9%)	(6.0%)	(0.9%)
PROCRIT/EXPREX
US	950	1,014	(6.3%)	(6.3%)	-
Intl	719	886	(18.8%)	(9.0%)	(9.8%)
WW	1,669	1,900	(12.2%)	(7.6%)	(4.6%)
RAZADYNE/REMINYL
US	30	123	(75.6%)	(75.6%)	-
Intl	275	316	(13.0%)	(1.2%)	(11.8%)
WW	305	439	(30.5%)	(22.0%)	(8.5%)
REMICADE
US	2,330	2,138	9.0%	9.0%	-
US Exports (4)	821	718	14.3%	14.3%	-
Intl	15	6	150.0%	145.8%	4.2%
WW	3,166	2,862	10.6%	10.6%	-

Note: See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD
	$MM
	NINE MONTHS
			% Change
	2009	2008	Reported	Operational (1)	Currency
PHARMACEUTICAL SEGMENT (2) (CONTINUED)

RISPERDAL/RISPERIDONE
US	223	1,196	(81.4%)	(81.4%)	-
Intl	483	645	(25.1%)	(21.3%)	(3.8%)
WW	706	1,841	(61.7%)	(60.4%)	(1.3%)
RISPERDAL CONSTA
US	386	339	13.9%	13.9%	-
Intl	640	651	(1.7%)	12.6%	(14.3%)
WW	1,026	990	3.6%	13.0%	(9.4%)
TOPAMAX
US	642	1,674	(61.6%)	(61.6%)	-
Intl	317	377	(15.9%)	(3.5%)	(12.4%)
WW	959	2,051	(53.2%)	(50.9%)	(2.3%)
VELCADE
US	-	4	(100.0%)	(100.0%)	-
Intl	652	575	13.4%	26.7%	(13.3%)
WW	652	579	12.6%	25.8%	(13.2%)
OTHER
US	2,009	1,858	8.1%	8.1%	-
Intl	2,553	2,567	(0.5%)	9.2%	(9.7%)
WW	4,562	4,425	3.1%	8.8%	(5.7%)
TOTAL PHARMACEUTICAL
US	9,703	11,401	(14.9%)	(14.9%)	-
Intl	6,824	7,481	(8.8%)	1.4%	(10.2%)
WW	16,527	18,882	(12.5%)	(8.5%)	(4.0%)
MAJOR NEW PHARMACEUTICAL PRODUCTS (5)
PREZISTA
US	215	109	97.2%	97.2%	-
Intl	198	132	50.0%	70.0%	(20.0%)
WW	413	241	71.4%	82.3%	(10.9%)
INVEGA
US	194	192	1.0%	1.0%	-
Intl	93	39	138.5%	168.1%	(29.6%)
WW	287	231	24.2%	29.2%	(5.0%)
Note: See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD
$MM
THIRD QUARTER
		% Change
2009	2008	Reported	Operational (1)	Currency

MEDICAL DEVICES AND DIAGNOSTICS   (2) (3)
CORDIS (6)
US	233	259	(10.0%)	(10.0%)	-
Intl	407	431	(5.6%)	(4.6%)	(1.0%)
WW	640	690	(7.2%)	(6.6%)	(0.6%)
DEPUY
US	740	698	6.0%	6.0%	-
Intl	544	533	2.1%	7.6%	(5.5%)
WW	1,284	1,231	4.3%	6.7%	(2.4%)
DIABETES CARE
US	332	349	(4.9%)	(4.9%)	-
Intl	302	318	(5.0%)	(0.4%)	(4.6%)
WW	634	667	(4.9%)	(2.7%)	(2.2%)
ETHICON
US	439	372	18.0%	18.0%	-
Intl	580	585	(0.9%)	3.8%	(4.7%)
WW	1,019	957	6.5%	9.4%	(2.9%)
ETHICON ENDO-SURGERY
US	499	473	5.5%	5.5%	-
Intl	607	569	6.7%	10.9%	(4.2%)
WW	1,106	1,042	6.1%	8.4%	(2.3%)
ORTHO-CLINICAL DIAGNOSTICS
US	285	261	9.2%	9.2%	-
Intl	216	209	3.3%	7.0%	(3.7%)
WW	501	470	6.6%	8.2%	(1.6%)
VISION CARE
US	238	236	0.8%	0.8%	-
Intl	421	416	1.2%	(0.2%)	1.4%
WW	659	652	1.1%	0.2%	0.9%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US	2,766	2,648	4.5%	4.5%	-
Intl	3,077	3,061	0.5%	3.8%	(3.3%)
WW	5,843	5,709	2.3%	4.1%	(1.8%)

Note: See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD
$MM
NINE MONTHS
		% Change
2009	2008	Reported	Operational (1)	Currency

MEDICAL DEVICES AND DIAGNOSTICS   (2) (3)
CORDIS (6)
US	731	929	(21.3%)	(21.3%)	-
Intl	1,251	1,375	(9.0%)	(3.9%)	(5.1%)
WW	1,982	2,304	(14.0%)	(10.9%)	(3.1%)
DEPUY
US	2,268	2,129	6.5%	6.5%	-
Intl	1,631	1,717	(5.0%)	6.8%	(11.8%)
WW	3,899	3,846	1.4%	6.7%	(5.3%)
DIABETES CARE
US	908	990	(8.3%)	(8.3%)	-
Intl	877	966	(9.2%)	0.2%	(9.4%)
WW	1,785	1,956	(8.7%)	(4.1%)	(4.6%)
ETHICON
US	1,296	1,087	19.2%	19.2%	-
Intl	1,717	1,835	(6.4%)	3.6%	(10.0%)
WW	3,013	2,922	3.1%	9.3%	(6.2%)
ETHICON ENDO-SURGERY
US	1,442	1,386	4.0%	4.0%	-
Intl	1,794	1,783	0.6%	10.6%	(10.0%)
WW	3,236	3,169	2.1%	7.7%	(5.6%)
ORTHO-CLINICAL DIAGNOSTICS
US	846	749	13.0%	13.0%	-
Intl	616	640	(3.8%)	4.8%	(8.6%)
WW	1,462	1,389	5.3%	9.3%	(4.0%)
VISION CARE
US	703	689	2.0%	2.0%	-
Intl	1,185	1,209	(2.0%)	0.3%	(2.3%)
WW	1,888	1,898	(0.5%)	0.9%	(1.4%)
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US	8,194	7,959	3.0%	3.0%	-
Intl	9,071	9,525	(4.8%)	3.7%	(8.5%)
WW	17,265	17,484	(1.3%)	3.3%	(4.6%)
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Prior year amounts have been reclassified to conform with current presentation
(4) Reported as U.S. sales
(5) Included in Other
(6) Includes sales of Drug-Eluting Stents for Q3 2009 of $53, $158 and $211MM Domestic, International       and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q3 2008 of $97, $192 and $289MM Domestic, International       and Worldwide respectively
Includes sales of Drug-Eluting Stents for September YTD 2009 of $189, $507 and $696MM Domestic,       International and Worldwide respectively
Includes sales of Drug-Eluting Stents for September YTD 2008 of $433, $650 and $1,083MM Domestic,       International and Worldwide respectively